Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 985 to 986 of 986 entries
Sorted by: Best Match Show Resources per page
Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer.

Cancers

Safi SA, Haeberle L, Rehders A, Fung S, Vaghiri S, Roderburg C, Luedde T, Ziayee F, Esposito I, Fluegen G, Knoefel WT.
PMID: 35008232
Cancers (Basel). 2021 Dec 23;14(1). doi: 10.3390/cancers14010068.

BACKGROUND: Survival following surgical treatment of ductal adenocarcinoma of the pancreas (PDAC) remains poor. The recent implementation of the circumferential resection margin (CRM) into standard histopathological evaluation lead to a significant reduction in R0 rates. Mesopancreatic fat infiltration is...

Cite
Safi SA, Haeberle L, Rehders A, et al. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers (Basel). 2021;14(1)doi: 10.3390/cancers14010068.
Safi, S. A., Haeberle, L., Rehders, A., Fung, S., Vaghiri, S., Roderburg, C., Luedde, T., Ziayee, F., Esposito, I., Fluegen, G., & Knoefel, W. T. (2021). Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers, 14(1), . https://doi.org/10.3390/cancers14010068
Safi, Sami-Alexander, et al. "Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer." Cancers vol. 14,1 (2021). doi: https://doi.org/10.3390/cancers14010068
Safi SA, Haeberle L, Rehders A, Fung S, Vaghiri S, Roderburg C, Luedde T, Ziayee F, Esposito I, Fluegen G, Knoefel WT. Neoadjuvant Treatment Lowers the Risk of Mesopancreatic Fat Infiltration and Local Recurrence in Patients with Pancreatic Cancer. Cancers (Basel). 2021 Dec 23;14(1). doi: 10.3390/cancers14010068. PMID: 35008232.
Copy Download .nbib Format: NLM
Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia.

The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques

Huang P, Li YY, Park JE, Huang P, Xiao Q, Wang Y, Chen S, Chen SD, Liu J, Wu YW.
PMID: 33685541
Can J Neurol Sci. 2021 Mar 09;1-6. doi: 10.1017/cjn.2021.42. Epub 2021 Mar 09.

We investigated the effects of botulinum toxin on gait in Parkinson's disease (PD) patients with foot dystonia. Six patients underwent onabotulinum toxin A injection and were assessed by Burke-Fahn-Marsden Dystonia Rating Scale (BFMDRS), visual analog scale (VAS) of pain,...

Cite
Huang P, Li YY, Park JE, et al. Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia. Can J Neurol Sci. 2021;1-6doi: 10.1017/cjn.2021.42.
Huang, P., Li, Y. Y., Park, J. E., Huang, P., Xiao, Q., Wang, Y., Chen, S., Chen, S. D., Liu, J., & Wu, Y. W. (2021). Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia. The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques, 1-6. https://doi.org/10.1017/cjn.2021.42
Huang, Pei, et al. "Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia." The Canadian journal of neurological sciences. Le journal canadien des sciences neurologiques vol. (2021): 1-6. doi: https://doi.org/10.1017/cjn.2021.42
Huang P, Li YY, Park JE, Huang P, Xiao Q, Wang Y, Chen S, Chen SD, Liu J, Wu YW. Effects of Onabotulinum Toxin A on Gait in Parkinson's Disease Patients with Foot Dystonia. Can J Neurol Sci. 2021 Mar 09;1-6. doi: 10.1017/cjn.2021.42. Epub 2021 Mar 09. PMID: 33685541.
Copy Download .nbib Format: NLM
Showing 985 to 986 of 986 entries